Login
$UPB
$2.18 +$0.03 (1.4%) After hours

$UPB SEC Filings

Filed On Filing
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

– Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 –

06 Nov 2026 SCHEDULE 13G/A
29 Oct 2026 SCHEDULE 13G/A
17 Sep 2026 Form 4: Gray Michael, CFO and COO

Sold 853 shares ($4.68K)

17 Sep 2026 Form 4: Ambrose Allison, General Counsel

Sold 485 shares ($2.66K)

17 Sep 2026 Form 4: Deykin Aaron, Chief Medical Officer

Sold 895 shares ($4.91K)

17 Sep 2026 Form 4: Sutherland Everett Rand, Director

Sold 2,095 shares ($11.5K)

17 Sep 2026 Form 4: Houghton Adam, Chief Business Officer

Sold 700 shares ($3.84K)

01 Sep 2026 8-K: Regulation FD Disclosure; Other Events

– Following productive FDA discussions, Upstream Bio will study 400mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication –

12 Aug 2026 SCHEDULE 13G/A
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track–

30 Jul 2026 SCHEDULE 13G
17 Jun 2026 Form 4: Gray Michael, CFO and COO

Sold 853 shares ($5.2K)

17 Jun 2026 Form 4: Sutherland Everett Rand, Director

Sold 2,095 shares ($12.8K)

17 Jun 2026 Form 4: Houghton Adam, Chief Business Officer

Sold 700 shares ($4.27K)

17 Jun 2026 Form 4: Deykin Aaron, Chief Medical Officer

Sold 895 shares ($5.46K)

17 Jun 2026 Form 4: Ambrose Allison, General Counsel

Sold 477 shares ($2.91K)

11 Jun 2026 Form 4: Ruddy Marcella K., Director

Granted 17,096 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support